Results 41 to 50 of about 13,154 (163)

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) [PDF]

, 2016
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
A, A, A, A, A, A, A, A, A, A, A, A, A, AA, AC, AH, AJ, AK, AK, AM, AW, B, B, B, B, BJ, C, C, C, C, CA, CA, CE, D, D, D, DG, DP, E, EA, EE, F, F, F, F, FA, FM, FM, G, G, G, G, G, G, G, GA, GP, H, H, H, H, HAS, HE, I, I, I, I, IJ, J, J, JA, JE, JF, JG, JJ, JJ, JL, JR, JR, JR, JV, K, K, K, K, KA, KC, KYY, L, LJ, M, M, M, M, M, M, M, M, M, M, M, M, M, MA, MA, MA, MA, MC, MG, MM, MN, MP, N, N, NT, O, OR, P, P, P, P, PF, PK, R, R, R, R, R, R, R, RB, RG, RM, RR, RR, RS, RV, S, S, S, S, S, S, S, S, S, Sartelli, SJ, SK, SK, SM, SR, SR, SY, T, T, TL, TM, V, V, VG, VN, W, W, W, WL, WR, Y, YF, YH, YR, YS, Z, ZJ   +173 more
core   +16 more sources

A prospective one-year microbiologic survey of combined pneumonia and respiratory failure [PDF]

, 2017
Background: Pneumonia and respiratory failure are common problems in the intensive care unit (ICU) setting, often occurring together. The relative prevalence of pneumonia types (community acquired, hospital acquired, ventilator associated) and causative ...
Fisher, Kristen, Juang, Paul, Kollef, Marin H, Micek, Scott T, Trupka, Tracy   +4 more
core   +2 more sources

WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases [PDF]

, 2017
Background: Several diazabicyclooctanes (DBOs) are under development as inhibitors of Class A and C -lactamases. Inhibition of OXA (Class D) carbapenemases is variable, with those of Acinetobacter spp. remaining notably resistant. We describe a novel DBO,
Anna Vickers, Clinical and Laboratory Standards Institute, David M. Livermore, Neil Woodford, Shazad Mushtaq   +4 more
core   +1 more source

Activity of OP0595-β-lactam combination against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactama [PDF]

, 2015
Background: OP0595 is a diazabicyclooctane that (i) acts as a PBP2-ctive antibacterial, (ii) inhibits Class A and C β-lactamases and (iii), like mecillinam, gives β-lactamase-independent potentiation of β-lactams targeting other PBPs.
Livermore, David M., Mushtaq, Shazad, Warner, Marina, Woodford, Neil   +3 more
core   +1 more source

Management of KPC-Producing Klebsiella pneumoniae Infections [PDF]

, 2015
Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic ...
M. Bassetti, D.R. Giacobbe, H. Giamarellou, C. Viscoli, G.L. Daikos, G. Dimopoulos, F.G. De Rosa, E.J. Giamarellos-Bourboulis, G.M. Rossolini, E. Righi, I. Karaiskos, M. Tumbarello, D.P. Nicolau, P.L. Viale, G. Poulakou, Rossolini, Munoz-Price, Grundmann, Maltezou, Giacobbe, Banerjee, Girmenia, Patel, Bauer, Arena, Kostrzewa, Rotova, Gaibani, Hoyos-Mallecot, Salimnia, Vincent, Arena, Paul, Zusman, Dickstein, Tzouvelekis, Tumbarello, Tumbarello, Daikos, Gutiérrez-Gutiérrez, Del Bono, Pea, Tenover, Clinical and Laboratory Standards Institute (CLSI), Nation, Capone, Monaco, Giacobbe, Giamarellou, Spyropoulou, Meletis, Karaiskos, Karaiskos, Sorlí, Sandri, Nation, Gonzalez-Padilla, Machuca, Stankowicz, Poulakou, Bassetti, Montravers, Bassetti, Ramirez, Wiskirchen, Giamarellou, Pontikis, Parker, Albiero, Lepak, Docobo-Pérez, Grabein, Shields, Temkin, Shields, Shields, Perez, Bulik, Giamarellou, Souli, Oliva, Cprek, Poulakou, Lu, Karvouniaris, Kollef, Rello, Solé-Lleonart, Palmer, Kalil, Monogue, Berthoin, Pea, Lorente, Ho, Kim, Keel, Martínez, Patel, Zarkotou, Falcone, Nguyen, de Oliveira, Dimopoulos, Chastre, Capellier, Havey, Matthaiou, Tacconelli, De Rosa, Sypsa, Gagliotti, Lin, Giacobbe, Munoz-Price, Tofteland, Schwaber, Lerner, De Rosa, Abdallah, Tumbarello, Giannella, Giannella, Giacobbe, Salsano, Sbrana, Girmenia, De Rosa, Forcina, Viale, Zuckerman, Saidel-Odes, Lübbert, Tascini, Oren, Tascini, Machuca, Bassetti, Falagas, Sutcliffe, Connors, Zhang, Solomkin   +142 more
core   +2 more sources

High-Level Ceftazidime/Avibactam Resistance in Escherichia coli Conferred by the Novel Plasmid-Mediated β-Lactamase Cmy-185 Variant [PDF]

, 2023
OBJECTIVES: To characterize a blaCMY variant associated with ceftazidime/avibactam resistance from a serially collected Escherichia coli isolate. METHODS: A patient with an intra-abdominal infection due to recurrent E.
Aitken, Samuel L, Bachman, William C, Bhatti, Micah M, Borjan, Jovan, Doi, Yohei, Egge, Stephanie L, Endres, Bradley T, Kawai, Akito, Khan, Ayesha, McElheny, Christi L, Miller, William R, Saharasbhojane, Pranoti, Shelburne, Samuel A, Shields, Ryan K, Shropshire, William C, Wu, Chin-Ting   +15 more
core   +2 more sources

Ceftazidime/Avibactam: Who Says You Can’t Teach an Old Drug New Tricks?

Journal of Pharmacy & Pharmaceutical Sciences, 2016
Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, unique,
Katie E. Barber, Jessica K. Ortwine, Ronda L Akins   +2 more
doaj   +1 more source

Evaluation of FilmArray Multiplex PCR Test Results in Bloodstream Infections in Oncological Patients

Journal of Clinical Laboratory Analysis, EarlyView.
In this study conducted at an oncology hospital, BCID2 panel results for the rapid identification of microorganisms and resistance genes in positive blood culture samples were compared with conventional culture methods. The BCID2 panel provided faster results and showed a high correlation with traditional methods.
İpek Mumcuoğlu, Sevgi Şahin, Esra Tavukcu, Neşe İnan, Ayşe Semra Güreser, Serap Süzük Yıldız, Tuba Dal   +6 more
wiley   +1 more source

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. [PDF]

, 2016
This study aimed to investigate the pharmacokinetics (PK), safety, and tolerability of a single dose of ceftazidime-avibactam in pediatric patients. A phase I, multicenter, open-label PK study was conducted in pediatric patients hospitalized with an ...
Armstrong, Jon, Arrieta, Antonio, Bishai, Raafat, Bradley, John S, Das, Shampa, Delair, Shirley, Edeki, Timi, Holmes, William C, Li, Jianguo, Moffett, Kathryn S, Mukundan, Deepa, Perez, Norma, Romero, José R, Speicher, David, Sullivan, Janice E, Zhou, Diansong   +15 more
core  

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Microbiology Spectrum, 2022
The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu, Xiaoya Wei, Yongxin Jin, Fang Bai, Zhihui Cheng, Shuiping Chen, Xiaolei Pan, Weihui Wu   +7 more
doaj   +1 more source